Brought to you by 
Novartis gets ex-US rights to Ophthotech’s wet AMD candidate Fovista
04 Jan 2018
Executive Summary
Ophthotech Corp. (eye disorder treatments) licensed Novartis Pharmaceuticals Corp. exclusive worldwide rights outside of the US to its pegylated aptamer Fovista (E10030; ARC127), a platelet-derived growth factor (PDGF) beta receptor antagonist in Phase III for wet age-related macular degeneration (AMD) either as a monotherapy or in combination with an anti-vascular endothelial growth factor (VEGF) agent (such as Lucentis, Avastin (bevacizumab), or Eylea (aflibercept)).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets ex-US rights to Ophthotech’s wet AMD candidate Fovista
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice